Compare
Talphera, Inc. vs Impact Biomedical Inc. vs Lyell Immunopharma, Inc. vs Neonc Technologies Holdings, Inc.
| Latest fiscal year | Talphera, Inc. TLPH | Impact Biomedical Inc. IBO | Lyell Immunopharma, Inc. LYEL | Neonc Technologies Holdings, Inc. NTHI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $28.0K | $32.0K | $36.0K | $40.0K |
| Revenue growth (YoY) | n/a | n/a | -41.0% | -51.8% |
| Gross margin | n/a | n/m (computed) | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$14.29M | -$11.84M | -$274.45M | -$62.15M |
| EPS (Diluted) | n/a | -$0.38 | -$16.06 | -$3.20 |
| Operating cash flow | -$11.36M | -$1.89M | -$150.02M | -$20.36M |
| Free cash flow | n/a | n/a | -$150.80M | -$20.86M |
| Cash & equivalents | $5.89M | $3.0K | $60.18M | $58.7K |
| Total assets | $29.72M | $17.41M | $340.05M | $2.82M |
| Total liabilities | $12.68M | $1.85M | $91.85M | $20.33M |
| Shareholders' equity | $17.04M | $12.61M | $248.20M | -$17.51M |
| Return on year-end equity | -83.9% | -93.9% | -110.6% | n/a |
| Shares outstanding | 49.33M | 104.62M | 21.25M | 21.99M |
Revenue, most recent five fiscal years
| Fiscal year | Talphera, Inc. | Impact Biomedical Inc. | Lyell Immunopharma, Inc. | Neonc Technologies Holdings, Inc. |
|---|---|---|---|---|
| Latest | $28.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $36.0K Ended 2025-12-31 | $40.0K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | n/a | $61.0K Ended 2024-12-31 | $83.0K Ended 2024-12-31 |
| 2 years earlier | $651.0K Ended 2023-12-31 | n/a | $130.0K Ended 2023-12-31 | n/a |
| 3 years earlier | $0 Ended 2022-12-31 | $50.0K Ended 2022-12-31 | $84.68M Ended 2022-12-31 | n/a |
| 4 years earlier | $2.82M Ended 2021-12-31 | n/a | $10.65M Ended 2021-12-31 | n/a |